RT Journal Article
T1 Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.
A1 Sarmiento-Maldonado, Mauricio
A1 Ramirez-Villanueva, Pablo
A1 Cortes-Monroy, Pablo Bertin
A1 Jara-Arias, Veronica
A1 Soto-Donoso, Katherine
A1 Uribe-Gonzalez, Pablo
A1 Ocqueteau-Tachini, Mauricio
A1 Perez-Simon, Jose Antonio
K1 Corticoid refractoriness
K1 Extracorporeal photopheresis
K1 Graft versus host disease
K1 Ruxolitinib
AB Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment.
SN 2162-3619
YR 2017
FD 2017-12-02
LK https://hdl.handle.net/10668/27873
UL https://hdl.handle.net/10668/27873
LA en
NO Sarmiento Maldonado M, Ramírez Villanueva P, Bertín Cortes-Monroy P, Jara Arias V, Soto Donoso K, Uribe Gonzalez P, et al. Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. Exp Hematol Oncol. 2017 Dec 2;6:32.
DS RISalud
RD Apr 18, 2025